Compare Credo Technology Group Holding Ltd (CRDO) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs Pfizer Inc — how do they compare? Credo Technology Group Holding Ltd trades at $211.77 (market cap $39.82B), while Pfizer Inc trades at $28.01 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 4× Credo Technology Group Holding Ltd's market cap, and Pfizer Inc pays a 6.18% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Credo Technology Group Holding Ltd for 22 Days and Pfizer Inc for 158 Days on average.
| CRDO | PFE | |
|---|---|---|
Market Cap | $39.82B | $158.56B |
Volume | 9,451,558 | 44,138,282 |
Sector | Technology | Health |
52-Week High | $302.52 | $29.02 |
52-Week Low | $87.81 | $23.67 |
Typical Hold Time | 22 Days | 158 Days |
Enterprise Value | $39.08B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $212.42, down 3.45% today but maintains strong technical support near $204 with bullish moving averages. The company demonstrates exceptional fundamentals with 114.7% YoY revenue growth (Seeking Alpha, 2026-09-25) and 33.83% net margins, though valuation remains elevated at P/E of 74.6. Recent earnings beats and AI infrastructure demand drive positive sentiment.
Outlook remains positive given triple-digit revenue growth and $267.33 analyst price target (87.5% buy ratings), but premium valuation and customer concentration pose risks. The stock offers exposure to AI connectivity chip demand with potential for 26% upside to consensus target, though execution risks require monitoring.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
